Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients (FORUM)

This study has been terminated.
(Due to poor patient enrollment)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00241462
First received: October 18, 2005
Last updated: April 21, 2009
Last verified: April 2009
  Purpose

The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.


Condition Phase
Breast Cancer
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 150
Study Start Date: June 2005
Estimated Study Completion Date: December 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal
  • Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
  • Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment

Exclusion Criteria:

  • Life threatening metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241462

Locations
Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Almelo, Netherlands
Research Site
Almere, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Assen, Netherlands
Research Site
Bergen op Zoom, Netherlands
Research Site
Capelle Aan Den Ijssel, Netherlands
Research Site
Delft, Netherlands
Research Site
Delfzijl, Netherlands
Research Site
Doetinchem, Netherlands
Research Site
Dokkum, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Drachten, Netherlands
Research Site
Ede Gld, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Gorinchem, Netherlands
Research Site
Hardenberg, Netherlands
Research Site
Heerenveen, Netherlands
Research Site
Heerlen, Netherlands
Research Site
Hellevoetsluis, Netherlands
Research Site
Hilversum, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Leiden, Netherlands
Research Site
Leiderdorp, Netherlands
Research Site
Leidschendam, Netherlands
Research Site
Meppel, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Oss, Netherlands
Research Site
Roermond, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
S-Gravenhage, Netherlands
Research Site
Stadskanaal, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Vlaardingen, Netherlands
Research Site
Winschoten, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zeist, Netherlands
Research Site
Zevenaar, Netherlands
Research Site
Zwolle, Netherlands
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Netherlands Medical Director, MD AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00241462     History of Changes
Other Study ID Numbers: D6997-NL-001, FORUM
Study First Received: October 18, 2005
Last Updated: April 21, 2009
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AstraZeneca:
Advanced Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014